ARTICLE | Clinical News
Cytokinetics begins Phase III CVOT trial of omecamtiv mecarbil
October 27, 2017 6:57 PM UTC
Cytokinetics Inc. (NASDAQ:CYTK) began the Phase III GALACTIC-HF cardiovascular outcomes trial (CVOT) trial evaluating twice-daily oral omecamtiv mercarbil (AMG 423) in about 8,000 patients with high-risk chronic heart failure and reduced ejection fraction. The double-blind, placebo-controlled, international trial's primary endpoint is time to cardiovascular death or first heart failure event. Secondary endpoints include change in patient-reported Kansas City Cardiomyopathy Questionnaire total symptom score...
BCIQ Target Profiles